You are here

Dicerna

Dicerna can’t catch up with Alnylam

EP Vantage

Mon, 08/9/21 - 10:50 am

Primary Hyperoxaluria

Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win

Endpoints

Thu, 08/5/21 - 11:24 pm

Primary Hyperoxaluria

clinical trials

Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug

BioSpace

Thu, 05/27/21 - 11:09 am

clinical trials

cardiometabolic diseases

Biotech’s important clinical data readouts

EP Vantage

Fri, 03/26/21 - 10:35 am

spinal muscular atrophy

Primary Hyperoxaluria

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Pharmaforum

Wed, 01/6/21 - 10:42 am

Dicerna nabs speedy review voucher for leading RNAi drug

Fierce Biotech

Thu, 06/18/20 - 10:36 am

priority review

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

Endpoints

Mon, 04/6/20 - 10:29 am

John Maraganore

Douglas Fambrough

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Mon, 11/18/19 - 11:33 pm

Eli Lilly makes bet on gene-silencing drug firm Dicerna

Yahoo/Reuters

Mon, 10/29/18 - 09:37 am

Biotech companies Alnylam, Dicerna settle trade secrets case

Reuters

Sat, 04/21/18 - 12:40 pm

Dicerna and Boehringer partner on RNAi treatment for NASH

Endpoints

Thu, 11/2/17 - 11:14 am

Boehringer Ingelheim

8 Biotech Stocks Under $10 Making Big Moves Higher

TheStreet.com

Sun, 03/20/16 - 01:16 pm

Novadaq Technologies

Idera Pharmaceuticals

Biotech Boomlet Set To Smash IPO Record For Two-Week Period

Seeking Alpha

Mon, 02/3/14 - 08:22 am